CareLit Fachartikel

Loss of ALCAM/CD166 partially protects against diabetic nephropathy

R von Bauer, A Sulaj, S Kopf, E Gröne, HJ Gröne, S Hoffmann, E Schleicher, HU Häring, V Schwenger, S Herzig, PP Nawroth, T Fleming · Diabetologie und Stoffwechsel · 2015 · Heft 04

Dokument
1084102
CareLit-ID
Jahr
2015
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Diabetologie und Stoffwechsel
Autor:innen
R von Bauer, A Sulaj, S Kopf, E Gröne, HJ Gröne, S Hoffmann, E Schleicher, HU Häring, V Schwenger, S Herzig, PP Nawroth, T Fleming
Ausgabe
Heft 04 / 2015
Seiten
–
Erschienen: 2015-04-29 00:00:00
ISSN
1861-9002
DOI
10.1055/s-0035-1549526

Zusammenfassung

Introduction/Background: Activated leukocyte cell adhesion molecule (ALCAM/CD166) has been shown to function as a pattern recognition receptor, analogue to the receptor of advanced glycation endproducts. In this study role of ALCAM in diabetic nephropathy was investigated in patients with type 2 diabetes, and further investigated in vitro and in vivo using homozygous knock-out mice for ALCAM (ALCAM-/-). Materials and methods: The serum concentration of soluble ALCAM (sALCAM), as well the expression of ALCAM and its major ligand, S100B in the kidney was determined in patients with type 2 diabetes. In vivo, diabet…

Schlagworte

ALCAM Activated-Leukocyte Cell Adhesion Molecule Diabetologie und Stoffwechsel